Rivastigimine

We presented the patient with relative younger Alzheimer’s disease (AD) whose clinical symptoms and cognitive functions were responsive not to donepezil but to rivastigmine. Age of initial visit our memory clinic of this patient was relatively younger. It is considered that in relative older patient both AD pathology and aging cause cognitive dysfunctions. Accordingly the ratio of BuChE/AChE increases. Therefore, when at mild stage such our patient, not donepezil but rivastigmine which has inhibiting actions on both AChE and BuChE was suitable.In Japan, two cholinesterase inhibitors (ChEIs), galantamine and rivastigmine, are marketed in 2011 in addition to donepezil. As one ChEI is not allowed to be combined with other ChEI, we should select one of three ChEIs for the patient Alzheimer’s disease (AD). We considered that donepezil was not effective because his wife complained that his demented state was not changed. We prescribed rivastigmine in stead of donepezi. A journal is a periodical publication intended to further progress of science, usually by reporting new research. Most journals are highly specialized, although some of the oldest journals publish articles, reviews, editorials, short communications, letters, and scientific papers across a wide range of scientific fields. Journals contain articles that peer reviewed, in an attempt to ensure that articles meet the journal's standards of quality, and scientific validity. Each such journal article becomes part of the permanent scientific record.

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on September, 2024